Table 3.
Single Nucleotide Polymorphisms (SNPs) statistically significantly associated with colorectal cancer (CRC) risk after Benjamini–Hochberg (BH) multiple testing correction, the EPIC study, 1992–2003.
| Gene/SNP/Genotype | CRC | Control | OR (95% CI) | P | PBH |
|---|---|---|---|---|---|
| FRZB/rs17265803 ^ | |||||
| AA | 844 | 976 | 1.00 (ref) | 3.04E-06 | 0.003 |
| AG | 315 | 240 | 1.56 (1.28,1.89) | ||
| Additive * | 1163 | 1232 | 1.35 (1.13,1.62) | 0.001 | 0.372 |
| Dominant (AG + GG vs. AA) | 1163 | 1232 | 1.48 (1.22,1.79) | 6.77E-05 | 0.034 |
| Recessive (GG vs. AA + AG) | 1163 | 1232 | 0.26 (0.09,0.80) | 0.018 | 0.747 |
| SMAD3/rs7180244 ^ | |||||
| GG | 994 | 1183 | 1.00 (ref) | 2.22E-16 | 1.12E-12 |
| GC | 372 | 198 | 2.33 (1.92,2.83) | ||
| Additive * | 1372 | 1388 | 2.16 (1.79,2.60) | 1.11E-15 | 3.74E-12 |
| Dominant (GC + CC vs. GG) | 1372 | 1388 | 2.28 (1.88,2.77) | 1.11E-16 | 1.12E-12 |
| Recessive (CC vs. GG + GC) | 1372 | 1388 | 0.87 (0.29,2.61) | 0.804 | 0.997 |
| SMAD7/rs11874392 | |||||
| AA | 478 | 400 | 1.00 (ref) | 1.39E-07 | 2.82E-04 |
| AT | 704 | 671 | 0.88 (0.74,1.04) | ||
| TT | 222 | 337 | 0.55 (0.44,0.68) | ||
| Additive * | 1404 | 1408 | 0.75 (0.68,0.84) | 1.99E-07 | 3.36E-04 |
| Dominant (AT + TT vs. AA) | 1404 | 1408 | 0.77 (0.65,0.90) | 0.001 | 0.372 |
| Recessive (TT vs. AA + AT) | 1404 | 1408 | 0.59 (0.49,0.72) | 6.26E-08 | 1.58E-04 |
| SMAD7/rs12953717 | |||||
| GG | 366 | 470 | 1.00 (ref) | 3.47E-05 | 0.019 |
| GA | 671 | 643 | 1.36 (1.14,1.62) | ||
| AA | 335 | 273 | 1.60 (1.29,1.98) | ||
| Additive * | 1372 | 1386 | 1.27 (1.14,1.41) | 9.07E-06 | 0.006 |
| Dominant (GA + AA vs. GG) | 1372 | 1386 | 1.43 (1.21,1.68) | 2.38E-05 | 0.014 |
| Recessive (AA vs. GG + GA) | 1372 | 1386 | 1.32 (1.10,1.59) | 0.003 | 0.534 |
| SMAD7/rs4939827 | |||||
| AA | 433 | 378 | 1.00 (ref) | 6.46E-06 | 0.005 |
| AG | 664 | 634 | 0.92 (0.77,1.09) | ||
| GG | 248 | 357 | 0.60 (0.49,0.75) | ||
| Additive * | 1345 | 1369 | 0.79 (0.71,0.87) | 9.46E-06 | 0.006 |
| Dominant (AG + GG vs. AA) | 1345 | 1369 | 0.80 (0.68,0.95) | 0.009 | 0.697 |
| Recessive (GG vs. AA + AG) | 1345 | 1369 | 0.64 (0.53,0.77) | 1.66E-06 | 0.002 |
| SMAD7/rs6507874 | |||||
| AA | 467 | 389 | 1.00 (ref) | 1.93E-06 | 0.002 |
| AG | 705 | 677 | 0.87 (0.73,1.03) | ||
| GG | 234 | 336 | 0.57 (0.46,0.71) | ||
| Additive * | 1406 | 1402 | 0.77 (0.69,0.86) | 1.26E-06 | 0.002 |
| Dominant (AG + GG vs. AA) | 1406 | 1402 | 0.77 (0.65,0.90) | 0.001 | 0.420 |
| Recessive (GG vs. AA + AG) | 1406 | 1402 | 0.63 (0.52,0.76) | 1.16E-06 | 0.002 |
^ = Results for the rare homozygous genotypes are omitted for these SNPs due to the small sample numbers with these genotypes; * = Additive models impose a structure in which each additional copy of the variant allele increases the response (log odds ratio) by the same amount. EPIC = European Prospective Investigation into Cancer and Nutrition.